ReviewExpert opinion on therapeutic targets2018
Therapeutic targets for the treatment of microsporidiosis in humans.
Review in Expert opinion on therapeutic targets, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- A global overview of microsporidia infection in HIV/AIDS patients: an updated systematic review and meta-analysis.International health · 2026Pooled it
- The Caenorhabditis elegans microbiome impacts microsporidia infection through nutrient limitation and spore inactivation.Nature communications · 2026Article
- Worms About Town: a citizen science project discovers microsporidian parasites of nematodes through environmental sampling.Biology open · 2026Article
- Identification of natural products and synthetic analogs which inhibit microsporidia spores and prevent infection.Journal of invertebrate pathology · 2026Article
- Small-molecule screen in C. elegans identifies benzenesulfonamides as inhibitors of microsporidia spores.npj antimicrobials and resistance · 2025Article
- Therapeutic Potential of Propolis and Royal Jelly in Encephalitozoon Intestinalis Infection: An in Vitro Study.Acta parasitologica · 2025Article
- Establishment and application of a loop-mediated isothermal amplification method based onFrontiers in veterinary science · 2025Article
- End-point RPA-CRISPR/Cas12a-based detection of Enterocytozoon bieneusi nucleic acid: rapid, sensitive and specific.BMC veterinary research · 2024Article
- Transgenic overexpression of bmo-miR-6498-5p increases resistance toApplied and environmental microbiology · 2024Article
- Investigation of the Infection ofVeterinary sciences · 2024Article
- Enterocytozoon bieneusi Infection after Hematopoietic Stem Cell Transplant in Child, Argentina.Emerging infectious diseases · 2024Article
- Article
- Molecular characterization and phylogenetic analyses of MetAP2 gene and protein ofFrontiers in veterinary science · 2024Article
- Screening of the Pandemic Response Box identifies anti-microsporidia compounds.PLoS neglected tropical diseases · 2023Article
- Dynamic Interplay of Metabolic and Transcriptional Responses in Shrimp during Early and Late Infection Stages ofInternational journal of molecular sciences · 2023Article
- Assessment of Oral Albendazole and Fumagillin in the Treatment ofComparative medicine · 2023Article
- Synthesis, Antimicrobial and Antibiofilm Activities, and Molecular Docking Investigations of 2-(1Molecules (Basel, Switzerland) · 2023Article
- Molecular characteristics and zoonotic potential of enteric protists in domestic dogs and cats in Egypt.Frontiers in veterinary science · 2023Article
- In Vivo Inhibitory Assessment of Potential Antifungal Agents onPathogens (Basel, Switzerland) · 2022Article
- High-throughput small molecule screen identifies inhibitors of microsporidia invasion and proliferation in C. elegans.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionMicrosporidia have been increasingly reported to infect humans. The most common presentation of microsporidiosis is chronic diarrhea, a significant mortality risk in immune-compromised patients. Albendazole, which inhibits tubulin, and fumagillin, which inhibits methionine aminopeptidase type 2 (MetAP2), are the two main therapeutic agents used for treatment of microsporidiosis. In addition, to their role as emerging pathogens in humans, microsporidia are important pathogens in insects, aquaculture, and veterinary medicine. New therapeutic targets and therapies have become a recent focus of attention for medicine, veterinary, and agricultural use. Areas covered: Herein, we discuss the detection and symptoms of microsporidiosis in humans and the therapeutic targets that have been utilized for the design of new drugs for the treatment of this infection, including triosephosphate isomerase, tubulin, MetAP2, topoisomerase IV, chitin synthases, and polyamines. Expert opinion: Enterocytozoon bieneusi is the most common microsporidia in human infection. Fumagillin has a broader anti-microsporidian activity than albendazole and is active against both Ent. bieneusi and Encephaliozoonidae. Microsporidia lack methionine aminopeptidase type 1 and are, therefore, dependent on MetAP2, while mammalian cells have both enzymes. Thus, MetAP2 is an essential enzyme in microsporidia and new inhibitors of this pathway have significant promise as therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.